Roche and Hanmi Pharmaceutical Invest $2.3 Billion in Muscle-Preserving Obesity Drug HM17321
$2.3 Billion Non-Incretin Technology Deal
Genentech, a subsidiary of Roche Holding AG (ROG), has secured exclusive global rights (excluding Korea) for the development, manufacturing, and commercialization of Hanmi Pharmaceutical's obesity candidate HM17321. The total contract value is up to USD 2.305 billion, comprising a non-repayable upfront payment of USD 190 million, potential development, approval, and commercialization milestones of up to USD 2.115 billion, and tiered royalties tied to net sales. The rationale for allocating a large upfront payment to a Phase 1 asset is its strategic value in the GLP-1-centric market, offering differentiation not only in weight loss but also in body composition improvement.
HM17321 Targets CRF2 Receptor
Known by its developmental name HM17321 or LA-UCN2 (not a brand name), this drug is a long-acting urocortin-2 analog that selectively activates the corticotropin-releasing factor-2 receptor (CRF2). In Hanmi Pharmaceutical's animal studies, both monotherapy and combination therapy with GLP-1 demonstrated signals of reducing body weight and fat mass while preserving and improving lean body mass and muscle function. Unlike incretins, which primarily rely on appetite suppression, HM17321 leverages fat breakdown promotion and fat formation inhibition, which is a key reason Roche assigned high value to its first-in-class potential.
FDA Phase 1 Trial Initiated in Humans
The U.S. FDA approved the clinical trial protocol for HM17321 on October 4, 2025, and the ongoing Phase 1 trial (NCT07219589) is currently enrolling healthy volunteers and obese participants. This randomized, double-blind, placebo-controlled, single and repeat dose-escalation study evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous injection. Since it is not yet at the efficacy confirmation stage, the key investment considerations are whether fat mass reduction and lean body mass preservation are simultaneously reproducible in humans, and whether CRF2 activation remains within an acceptable safety range.
Adding Combination Options to Wegovy and Zepbound-Dominated Market
Standard competitors include Novo Nordisk (NVO)'s Wegovy (active ingredient: semaglutide, target: GLP-1 receptor) and Eli Lilly (LLY)'s Zepbound (active ingredient: tirzepatide, target: GIP-GLP-1 receptors). Both products received FDA obesity indication approvals on June 4, 2021, and November 8, 2023, respectively, and are currently on the market without advisory committee votes during the approval process. Goldman Sachs forecasts the global obesity treatment market to reach USD 95 billion by 2030. Roche can combine HM17321 with its own CT-388 and Zealand Pharma (ZEAL)'s Phase 2 amylin analog petrelintide, potentially expanding the competition from weight loss rates to body composition and maintenance therapies.
The USD 190 million upfront payment and total deal value of up to USD 2.305 billion demonstrate that Roche Holding AG (ROG) evaluates the CRF2-based muscle-preserving mechanism of HM17321 as a core obesity platform. In the short term, the safety and pharmacodynamic results of NCT07219589 will serve as the first validation point for Hanmi Pharmaceutical (128940)'s milestone visibility and Roche's pipeline value. From a research perspective, the key translation task is whether GLP-1-independent fat reduction in humans leads to lean body mass preservation. In the medium to long term, HM17321 could either compete independently or be combined with CT-388 and petrelintide against Wegovy and Zepbound in the USD 95 billion market expected by 2030, but the majority of its current value depends on the clinical reproducibility of preclinical body composition signals.